SCHEMBL5249802

SCHEMBL5249802

O=S(=O)(c1ccc(Cl)cc1)N1CCC(O)CC1

nearest known ligand 0.71

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.71
ALDH1A1 P00352 3/20 0.63
PKM P14618 1/20 0.63
CNR1 P21554 1/20 0.61
KMT2A Q03164 4/20 0.61
MEN1 O00255 3/20 0.61
ATM Q13315 1/20 0.60
TP53 P04637 1/20 0.60
MAPT P10636 1/20 0.60
MAPK1 P28482 1/20 0.59
HSD11B1 P28845 1/20 0.58
NPSR1 Q6W5P4 1/20 0.57
SMN1; SMN2 Q16637 2/20 0.57
L3MBTL1 Q9Y468 2/20 0.57
KDM4E B2RXH2 1/20 0.57
CYP3A4 P08684 1/20 0.57
HTT P42858 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5254329 0.90 LMNA (0.62) LMNAALDH1A1PKMCNR1KMT2A
SCHEMBL5915284 0.90 LMNA (0.62) LMNAALDH1A1PKMCNR1KMT2A
SCHEMBL12793343 0.84 USP2 (0.71) LMNAALDH1A1KMT2AMEN1MAPT
SCHEMBL5252305 0.83 LMNA (0.67) LMNAALDH1A1PKMCNR1KMT2A
SCHEMBL10355428 0.83 ATM (0.81) LMNAALDH1A1PKMCNR1KMT2A
SCHEMBL4580893 0.83 ATM (0.81) LMNAALDH1A1PKMCNR1KMT2A
SCHEMBL266385 0.83 LMNA (1.00) LMNAALDH1A1PKMKMT2AMEN1
SCHEMBL15800491 0.83 HSD11B1 (0.58) LMNAALDH1A1PKMKMT2AMEN1
SCHEMBL5250428 0.83 LMNA (0.71) LMNAALDH1A1PKMCNR1KMT2A
SCHEMBL4940237 0.83 ALDH1A1 (0.64) LMNAALDH1A1PKMKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1758884-A2 N-CYCLIC SULFONAMIDO INHIBITORS OF GAMMA SECRETASE Elan Pharmaceuticals, Inc. (US) 2007-03-07 EP claimed
US-20060035884-A1 N-cyclic sulfonamido inhibitors of gamma secretase ELAN PHARMACEUTICALS, INC. (US) 2006-02-16 US claimed
WO-2005113542-A2 N-CYCLIC SULFONAMIDO INHIBITORS OF GAMMA SECRETASE ELAN PHARMACEUTICALS, INC. (US) 2005-12-01 WO claimed
US-20060035884-A1 N-cyclic sulfonamido inhibitors of gamma secretase ELAN PHARMACEUTICALS, INC. (US) 2006-02-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060035884-A1 N-cyclic sulfonamido inhibitors of gamma secretase BACE1, BACE2, APH1B LMNA 2570/4885ALDH1A1 2985/4885PKM 4290/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.